Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.46 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24334495 | 0.90 | SMN1; SMN2 (0.47) | SMN1; SMN2HPGDKMT2AALDH1A1TSHR | |
| SCHEMBL27370875 | 0.89 | CHRNB2 (0.51) | SMN1; SMN2HPGDKMT2ACHRNB2CHRNA3 | |
| SCHEMBL24321070 | 0.87 | HSD11B1 (0.54) | SMN1; SMN2HPGDKMT2AALDH1A1HTT | |
| SCHEMBL12327243 | 0.83 | CHRNB2 (0.46) | SMN1; SMN2HPGDKMT2ACHRNB2CHRNA3 | |
| SCHEMBL12396094 | 0.81 | EPHX2 (0.46) | KMT2ACHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL19608502 | 0.81 | HPGD (0.48) | SMN1; SMN2HPGDKMT2ACHRNB2CHRNA3 | |
| SCHEMBL19604768 | 0.81 | HPGD (0.48) | SMN1; SMN2HPGDCHRNB2CHRNA3CHRNA4 | |
| SCHEMBL797393 | 0.81 | KMT2A (0.42) | KMT2AMEN1 | |
| SCHEMBL4550273 | 0.81 | CYP4F2 (0.41) | KMT2ACYP4F2CYP4A11MEN1 | |
| SCHEMBL24321610 | 0.80 | CHRNB2 (0.46) | SMN1; SMN2KMT2ACHRNB2CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210113561-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-04-22 | — | — | US | disclosed |
| EP-3455216-B1 | PYRIDINYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF AS AOC3 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2020-11-04 | — | — | EP | disclosed |
| US-9926292-B2 | Pyridinyl derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-27 | — | — | US | disclosed |
| US-20170327483-A1 | Pyridinyl derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327483-A1 | Pyridinyl derivatives, pharmaceutical compositions and uses thereof | P2RY1, PNPO, P2RY4 | SMN1; SMN2 3492/4885HPGD 143/4885KMT2A 3504/4885 |
| US-20210113561-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | SLC5A2, SLC5A1, SLC2A3 | SMN1; SMN2 1626/4885HPGD 2621/4885KMT2A 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.